Several brokerages have updated their recommendations and price targets on shares of LumiraDx (NASDAQ: LMDX) in the last few weeks: 5/25/2022 – LumiraDx was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “LumiraDx Limited is a point of care diagnostics company. Its testing solutions are […]